Co-Diagnostics (CODX) 10-K 14 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 12, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38148
Entity Registrant Name	CO-DIAGNOSTICS, INC.
Entity Central Index Key	0001692415
Entity Tax Identification Number	46-2609396
Entity Incorporation, State or Country Code	UT
Entity Address, Address Line One	2401 S. Foothill Drive
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84109
City Area Code	(801)
Local Phone Number	438-1036
Title of 12(b) Security	Common Stock
Trading Symbol	CODX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float				$ 33,000,000
Entity Common Stock, Shares Outstanding			31,259,668
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	270	457
Auditor Name	Tanner LLC	Haynie & Company
Auditor Location	Salt Lake City, Utah	Salt Lake City, Utah

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 14,916,878	$ 22,973,803
Marketable investment securities	43,631,510	58,289,066
Accounts receivable, net	303,926	3,453,723
Inventory, net	1,664,725	5,310,473
Income taxes receivable	26,955	1,870,419
Prepaid expenses and other current assets	1,597,114	761,187
Note receivable		75,000
Total current assets	62,141,108	92,733,671
Property and equipment, net	3,035,729	2,539,483
Operating lease right-of-use asset	2,966,774	372,115
Intangible assets, net	26,403,667	26,768,333
Investment in joint venture	773,382	672,679
Total assets	95,320,660	123,086,281
Current liabilities
Accounts payable	1,482,109	952,296
Accrued expenses	2,172,959	934,447
Operating lease liability, current	838,387	297,209
Contingent consideration liabilities, current	891,666	1,689,471
Deferred revenue	362,449
Total current liabilities	5,747,570	3,873,423
Long-term liabilities
Income taxes payable	659,186	1,181,284
Deferred tax liability		2,417,987
Operating lease liability	2,152,180	50,708
Contingent consideration liabilities	748,109	1,042,885
Total long-term liabilities	3,559,475	4,692,864
Total liabilities	9,307,045	8,566,287
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022	36,108	34,754
Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively	(15,575,795)	(14,211,866)
Additional paid-in capital	96,808,436	88,472,935
Accumulated other comprehensive income	146,700	293,140
Accumulated earnings	4,598,166	39,931,031
Total stockholders’ equity	86,013,615	114,519,994
Total liabilities and stockholders’ equity	$ 95,320,660	$ 123,086,281

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock , shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	36,108,346	34,754,265
Common stock, shares outstanding	31,259,668	30,872,607
Treasury stock, shares	4,848,678	3,881,658

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 6,812,038	$ 34,218,209
Cost of revenue	4,184,949	5,481,093
Gross profit	2,627,089	28,737,116
Operating expenses
Sales and marketing	6,860,815	7,344,628
General and administrative	14,279,441	14,262,963
Research and development	22,962,593	17,438,098
Depreciation and amortization	1,230,474	1,282,718
Goodwill impairment charges		15,388,546
Total operating expenses	45,333,323	55,716,953
Loss from operations	(42,706,234)	(26,979,837)
Other income, net
Interest income	1,161,913	704,045
Realized gain on investments	2,243,059
Loss on disposition of assets	(2,578)	(138,117)
Gain on remeasurement of acquisition contingencies	1,092,581	7,899,644
Gain (loss) on equity method investment in joint venture	100,703	(332,969)
Total other income, net	4,595,678	8,132,603
Loss before income taxes	(38,110,556)	(18,847,234)
Income tax benefit	(2,777,691)	(4,608,985)
Net loss	(35,332,865)	(14,238,249)
Other comprehensive loss
Change in net unrealized gains on marketable securities, net of tax	(146,440)	293,140
Total other comprehensive income (loss)	(146,440)	293,140
Comprehensive loss	$ (35,479,305)	$ (13,945,109)
Loss per common share:
Basic	$ (1.20)	$ (0.45)
Diluted	$ (1.20)	$ (0.45)
Weighted average shares outstanding:
Basic	29,346,599	31,479,028
Diluted	29,346,599	31,479,028
Product Revenue [Member]
Total revenue	$ 991,473	$ 34,218,209
Grant Revenue [Member]
Total revenue	$ 5,820,565

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($)	Convertible Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 33,820		$ 80,271,999		$ 54,169,280	$ 134,475,099
Balance, shares at Dec. 31, 2021		33,819,862
Common stock issued for option exercises		$ 70		77,800			$ 77,870
Common stock issued for option exercises, shares		70,791					70,791
Common stock issued for warrant exercises		$ 50		99,950			$ 100,000
Common stock issued for warrant exercises, shares		50,000
Stock-based compensation expense		$ 725		7,542,498			7,543,223
Stock-based compensation expense, shares		725,166
Common stock issued for acquisitions		$ 89		480,687			480,776
Common stock issued for acquisitions, shares		88,446
Repurchases of common stock			(14,211,866)				(14,211,866)
Other comprehensive loss, net of tax					293,140		293,140
Net loss						(14,238,249)	(14,238,249)
Balance at Dec. 31, 2022		$ 34,754	(14,211,866)	88,472,935	293,140	39,931,031	$ 114,519,994
Balance, shares at Dec. 31, 2022		34,754,265
Common stock issued for option exercises, shares
Stock-based compensation expense		$ 1,354		8,335,501			$ 8,336,855
Stock-based compensation expense, shares		1,354,081
Repurchases of common stock			(1,363,929)				(1,363,929)
Other comprehensive loss, net of tax					(146,440)		(146,440)
Net loss						(35,332,865)	(35,332,865)
Balance at Dec. 31, 2023		$ 36,108	$ (15,575,795)	$ 96,808,436	$ 146,700	$ 4,598,166	$ 86,013,615
Balance, shares at Dec. 31, 2023		36,108,346

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net loss	$ (35,332,865)	$ (14,238,249)
Adjustments to reconcile net loss to cash (used in) provided by operating activities:
Depreciation and amortization	1,230,474	1,282,718
Goodwill impairment charges		15,388,546
Stock-based compensation expense	8,336,855	7,543,223
Change in fair value of acquisition contingencies	(1,092,581)	(7,899,644)
Non-cash lease expense	47,992	30,430
Realized gain on investments	(2,243,059)
(Gain) loss from equity method investment	(100,703)	332,969
Loss on disposition of assets	2,578	138,117
Deferred income taxes	(2,417,987)	(4,810,457)
Provision for credit losses	612,809	2,461,032
Inventory obsolescence expense	3,233,281	148,099
Changes in assets and liabilities:
Accounts receivable	2,536,988	14,924,427
Prepaid expenses and other assets	1,082,536	(224,094)
Inventory	413,140	(3,673,309)
Deferred revenue	362,449	(150,000)
Income taxes payable	(522,098)	(2,201,250)
Accounts payable, accrued expenses and other liabilities	1,768,326	(2,483,821)
Net cash (used in) provided by operating activities	(22,081,865)	6,568,737
Cash flows from investing activities
Purchases of property and equipment	(1,365,306)	(1,427,512)
Proceeds from maturities of marketable investment securities	127,251,619	11,255,266
Purchases of marketable securities	(110,497,444)	(67,995,926)
Net cash (used in) provided by investing activities	15,388,869	(58,168,172)
Cash flows from financing activities
Proceeds from exercise of options and warrants		177,870
Repurchases of common stock	(1,363,929)	(14,211,866)
Net cash (used in) financing activities	(1,363,929)	(14,033,996)
Net decrease in cash and cash equivalents	(8,056,925)	(65,633,431)
Cash and cash equivalents at beginning of period	22,973,803	88,607,234
Cash and cash equivalents at end of period	14,916,878	22,973,803
Supplemental disclosure of cash flow information
Interest paid
Income taxes paid	55,975	4,498,742
Supplemental disclosure of non-cash investing and financing transactions
Inventory moved to property, plant and equipment	673	218,906
Right-of-use assets obtained in exchange for new operating lease liabilities	3,203,146	681,327
Business acquisition measurement period adjustments		1,593
Fair value of common stock issued as consideration for business acquisitions		480,776
Fair value of contingent common stock issued as consideration for business acquisitions		$ 199,359

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (35,332,865)	$ (14,238,249)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Overview and Basis of Presentat

Overview and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Overview and Basis of Presentation	Note 1 – Overview and Basis of Presentation Description of Business Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include inventories, receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates. Basis of Presentation The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents. Marketable Investment Securities The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented. Accounts Receivable Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $ 504,264 200,338 303,926 6,552,249 3,098,526 3,453,723 Equity-Method Investments Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations. Inventory Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $ 1,664,725 700,467 964,258 5,310,473 1,327,264 3,983,209 2,760,011 0 Goodwill and Intangible Assets Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives. During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $ 0 15,388,546 Long-lived Assets Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value. Revenue Recognition The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue. Grant Revenue The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $ 5.8 0.3 Deferred Revenue Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied. Research and Development Research and development costs are expensed when incurred. The Company recorded $ 22,962,593 17,438,098 Stock-based Compensation The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture. Income Taxes The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority. Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies. Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows. Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period. Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive. Comprehensive Income (Loss) Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes. Concentrations Risk and Significant Customers The Company had certain customers which were each responsible for generating 10 28 37 100 Three customers accounted for more than 10 97 61 Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

Cash, Cash Equivalents, and Fin

Cash, Cash Equivalents, and Financial Instruments	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, and Financial Instruments	Note 3 – Cash, Cash Equivalents, and Financial Instruments The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category: Schedule of Cash, Cash Equivalents and Marketable Investment Securities December 31, 2023 Adjusted Cost Allowance for Credit Losses Total Unrealized Gains / (Losses) Fair Value Cash and Cash Equivalents Marketable Investment Securities Cash $ 4,317,449 $ - $ - $ 4,317,449 $ 4,317,449 $ - Level 1: Money market funds 10,599,429 - - 10,599,429 10,599,429 - Subtotal 10,599,429 - - 10,599,429 10,599,429 - Level 2: U.S. treasury securities 43,484,810 - 146,700 43,631,510 - 43,631,510 Subtotal 43,484,810 - 146,700 43,631,510 - 43,631,510 Total $ 58,401,688 $ - $ 146,700 $ 58,548,388 $ 14,916,878 $ 43,631,510 December 31, 2022 Adjusted Cost Allowance for Credit Losses Total Unrealized Gains / (Losses) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 12,834,444 $ - $ - $ 12,834,444 $ 12,834,444 $ - Level 1: Money market funds 146,359 - - 146,359 146,359 - Subtotal 146,359 - - 146,359 146,359 - Level 2: U.S. treasury securities 67,892,825 - 389,241 68,282,066 9,993,000 58,289,066 Subtotal 67,892,825 - 389,241 68,282,066 9,993,000 58,289,066 Total $ 80,873,628 $ - $ 389,241 $ 81,262,869 $ 22,973,803 $ 58,289,066 Marketable investment securities held as of December 31, 2023 mature over the next 12 months.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following three levels of inputs are used to measure the fair value of financial assets and liabilities: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy: Schedule of Fair Value Assets and Liabilities (Level 1) (Level 2) (Level 3) Total December 31, 2023 (Level 1) (Level 2) (Level 3) Total Assets: Cash equivalents $ 13,806,864 $ - $ - $ 13,806,864 Marketable securities (U.S. treasury bills and notes) - 43,631,510 - 43,631,510 Total assets measured at fair value $ 13,806,864 $ 43,631,510 $ - $ 57,438,374 Liabilities: Contingent consideration - common stock $ - $ - $ 1,318,995 $ 1,318,995 Contingent consideration - warrants - - 320,780 320,780 Total liabilities measured at fair value $ - $ - $ 1,639,775 $ 1,639,775 (Level 1) (Level 2) (Level 3)  Total December 31, 2022 (Level 1) (Level 2) (Level 3) Total Assets: Cash equivalents $ 186,667 $ 9,993,000 $ - $ 10,179,667 Marketable securities (U.S. treasury bills and notes) - 58,289,066 - 58,289,066 Total assets measured at fair value $ 186,667 $ 68,282,066 $ - $ 68,468,733 Liabilities: Contingent consideration - common stock $ - $ - $ 2,499,147 $ 2,499,147 Contingent consideration - warrants - - 233,209 233,209 Total liabilities measured at fair value $ - $ - $ 2,732,356 $ 2,732,356 The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit and U.S. treasury bills and notes as of December 31, 2023 and 2022, respectively. In connection with prior year acquisitions, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock, both to be issued when certain milestones are achieved. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement. The changes for Level 3 items measured at fair value on a recurring basis are as follows: Schedule of Changes in the Fair Value Measurement Fair value as of December 31, 2022 $ 2,732,356 Change in fair value of contingent consideration issued for business acquisitions (1,092,581 ) Fair value as of December 31, 2023 $ 1,639,775 The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs: Schedule of Contingent Consideration Common Stock and Warrants December 31, 2023 December 31, 2022 Stock price $ 1.33 $ 2.52 Strike price $ 9.13 $ 9.13 Volatility 187.5 % 75.0 % Risk-free rate 4.0 % 4.1 % Expected term (years) 3.0 4.0 Fair Value of Other Financial Instruments The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment Property and equipment, net consisted of the following: Schedule of Property and Equipment Estimated December 31, Useful Lives in years 2023 2022 Lab equipment 3 5 $ 4,545,908 $ 3,574,730 Leasehold improvements 0 5 548,648 224,957 Office equipment, furniture and other 2 5 173,668 112,044 Less accumulated depreciation and amortization (2,232,495 ) (1,372,248 ) Fixed assets, net $ 3,035,729 $ 2,539,483

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 6 – Goodwill and Intangible Assets Goodwill Goodwill represents the excess of purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. The following table presents the changes in the carrying amount of goodwill: Schedule of Goodwill Balance as of December 31, 2021 $ 14,706,818 Measurement period adjustments 681,728 Goodwill impairment charges (15,388,546 ) Balance as of December 31, 2022 $ - The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. The Company estimates the fair value of its reporting unit by using forecasts of discounted future cash flows and peer market multiples. If the fair value is less than the carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value. The Company performed a qualitative and quantitative goodwill impairment assessment as of December 31, 2022. Based on the impairment assessment performed the Company concluded that it was more likely than not that the fair value of the Company’s reporting unit was less than it’s carrying amount. Accordingly, the Company recorded an impairment charge to reduce the carrying value of goodwill to $ 0 Intangible Assets, Net Intangible assets, net consisted of the following: Schedule of Intangible Assets, Net December 31, 2023 Weighted-Average Gross Net Useful Life (1) Carrying Accumulated Carrying (in Years) Amount Amortization Amount In-process research and development Indefinite $  26,101,000 $ - $ 26,101,000 Non-competition agreements 2.7 1,094,000 (791,333 ) 302,667 Total intangible assets $ 27,195,000 $ (791,333 ) $ 26,403,667 December 31, 2022 Weighted-Average Gross Net Useful Life (1) Carrying Accumulated Carrying (in Years) Amount Amortization Amount In-process research and development Indefinite $ 26,101,000 $ - $ 26,101,000 Non-competition agreements 2.7 1,094,000 (426,667 ) 667,333 Total intangible assets $ 27,195,000 $ (426,667 ) $ 26,768,333 (1) Based on weighted-average useful life established as of the acquisition date. The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows: Schedule of Future Amortization Expense Year Ending December 31, Amortization Expense 2024 302,667 Total $ 302,667

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 7 - Accrued Expenses Accrued expenses consisted of the following: Schedule of Accrued Expenses December 31, 2023 December 31, 2022 Payroll liabilities $ 1,643,186 $ 428,354 Distributor commissions 9,958 159,725 Other accrued liabilities 519,815 346,368 Total accrued expenses $ 2,172,959 $ 934,447

Revenue

Revenue	12 Months Ended
	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Note 8 – Revenue The following table sets forth revenue by geographic area: Summary of Revenue by Geographic Area 2023 2022 Years Ended December 31, 2023 2022 United States Product revenue $ 659,618 $ 24,671,554 Grant revenue 5,820,565 - Total United States 6,480,183 24,671,554 Rest of World Product revenue 331,855 9,546,655 Grant revenue - - Total Rest of World 331,855 9,546,655 Total $ 6,812,038 $ 34,218,209 Revenue geographic area $ 6,812,038 $ 34,218,209 Percentage of revenue by area: United States 95 % 72 % Rest of World 5 % 28 % Deferred Revenue Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows: Schedule of Deferred Revenue Balance as of December 31, 2022 $ - Increase due to prepayments from customers 32,570 Increase due to grant funding awarded 329,879 Balance as of December, 2023 $ 362,449

Earnings per Share

Earnings per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share	Note 9 – Earnings per Share The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022: Schedule of Basis and Diluted Earnings Per Share 2023 2022 Years Ended December 31, 2023 2022 Numerator Net loss, as reported $ (35,332,865 ) $ (14,238,249 ) Denominator Weighted average shares, basic 29,346,599 31,479,028 Dilutive effect of stock options, warrants and RSUs - - Shares used to compute diluted earnings per share 29,346,599 31,479,028 Basic earnings per share $ (1.20 ) $ (0.45 ) Diluted earnings per share $ (1.20 ) $ (0.45 ) The computation of diluted earnings per share for the years ended December 31, 2023 and December 31, 2022 also excludes approximately 1.4 465,000 As a result of incurring a net loss for the years ended December 31, 2023 and 2022, respectively, no 2,618,362 512,112 1,443,238 50,000

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 10 – Stock-Based Compensation Stock Incentive Plans The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022 the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 4,357,937 Stock Options The following table summarizes option activity during the years ended December 31, 2023 and 2022: Schedule of Option Activity Number of Options Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2021 1,111,363 $ 2.12 $ 1.31 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised (70,791 ) 1.10 0.51 Outstanding at December 31, 2022 1,040,572 $ 2.19 $ 1.37 5.88 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised - - - Outstanding at December 31, 2023 1,040,572 $ 2.19 $ 1.37 4.89 Exercisable at December 31, 2023 1,040,572 $ 2.19 $ 1.37 4.89 The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022, respectively, was $ 0 0.4 0.2 0.8 Restricted Stock Units The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022: Schedule of Outstanding Restricted Stock Units and Related Party Number of RSUs Weighted Average Grant Date Fair Value Unvested at December 31, 2021 1,267,415 $ 9.94 Granted 1,925,476 5.66 Vested (725,166 ) 8.66 Forfeited/Cancelled (41,000 ) 8.31 Unvested at December 31, 2022 2,426,725 $ 6.95 Granted 1,948,750 1.92 Vested (1,354,081 ) 6.17 Forfeited/Cancelled (95,897 ) 6.16 Unvested at December 31, 2023 2,925,497 $ 3.99 As of December 31, 2023, there was $ 9.5 1.7 Warrants The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services. The following table summarizes warrant activity during the years ended December 31, 2023 and 2022: Schedule of Warrant Activity Number of Warrants Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2021 526,281 $ 8.15 $ 4.01 4.7 Issued for adjustments to contingent purchase consideration 8,719 9.13 1.88 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised (50,000 ) 2.00 1.22 Outstanding at December 31, 2022 485,000 $ 8.81 $ 2.43 4.0 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised - - - Outstanding at December 31, 2023 485,000 $ 8.81 $ 1.29 3.0 The intrinsic value of warrants exercised during the years ended December 31, 2023 and 2022, respectively, was $ 0 0.3 0 The total number of warrants exercisable at December 31, 2023 is 20,000 465,000 Stock-Based Compensation Expense The Company recognized stock-based compensation expense as follows: Schedule of Recognized Stock-based Compensation Expense 2023 2022 Years Ended December 31, 2023 2022 Cost of sales $ 46,586 $ 63,058 Sales and marketing 2,153,974 1,866,116 General and administrative 4,933,822 4,050,967 Research and development 1,202,473 1,563,082 Total stock-based compensation expense $ 8,336,855 $ 7,543,223

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 11 – Income Taxes The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022: Schedule of Components Income Tax Provision 2023  2022 Year Ended December 31, 2023 2022 Current: Federal $ 84,435 $ 563,821 State (540,240 ) (266,248 ) Total current $ (455,805 ) $ 297,573 Deferred: Federal (7,228,611 ) (3,945,090 ) State (2,068,509 ) (961,468 ) Change in valuation allowance 6,975,234 - Total deferred (2,321,886 ) (4,906,558 ) Total income tax benefit $ (2,777,691 ) $ (4,608,985 ) A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows: Schedule of Benefit from Income Taxes and Effective Tax Rates 2023 2022 Year Ended December 31, 2023 2022 Federal income tax expense at statutory rate 21.0 % 21.0 % State income tax expense, net of federal tax benefit 1.6 % 4.8 % Permanent differences: - Foreign derived intangible income deduction 0.0 % 1.4 % - Stock based compensation -3.5 % -3.6 % - Contingent consideration remeasurement 0.6 % 8.8 % - Goodwill impairment 0.0 % -17.1 % - Other permanent differences -0.2 % -0.6 % Research and development credits 4.6 % 11.1 % Change in uncertain tax positions 1.2 % -2.1 % Change in valuation allowance -18.3 % 0.0 % Other 0.3 % 0.8 % Effective income tax rate 7.3 % 24.5 % Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022: Schedule of Deferred Tax Assets and Liabilities 2023 2022 December 31, 2023 2022 Deferred tax assets: Accrued liabilities $ 58,158 $ 98,141 Reserves and allowances 734,631 765,004 Deferred compensation 620,551 566,076 Section 174 costs 7,337,629 3,460,159 Lease liability 742,131 85,899 UNICAP 43,943 168,936 Net operating loss carryforwards 4,040,601 - Research and development credits 1,688,255 - Total gross deferred tax assets 15,265,899 5,144,215 Less valuation allowance (6,938,829 ) - Total deferred tax assets 8,327,070 5,144,215 Deferred tax liabilities: Property and equipment, net (672,416 ) (609,261 ) Intangibles, net (6,552,255 ) (6,608,914 ) Prepaids (329,768 ) (156,053 ) Right of use asset (736,226 ) (91,873 ) Other comprehensive income (36,405 ) (96,101 ) Other - - Total deferred tax liabilities (8,327,070 ) (7,562,202 ) Net deferred tax liability $ - $ (2,417,987 ) At December 31, 2023, the Company had federal net operating loss carryforwards of $ 16.3 1.4 16.9 0.8 ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $ 1,078,431 1,469,577 Schedule of Unrecognized Tax Benefits December 31, 2023 2022 Unrecognized tax benefits at the beginning of the year $ 1,469,577 $ 1,067,853 Gross increases - current year tax positions 273,569 1,045,590 Gross increases - prior year tax positions 66,127 34,035 Gross decreases - prior year tax positions (730,842 ) (677,901 ) Unrecognized tax benefits at end of year $ 1,078,431 $ 1,469,577 Interest and penalties in year-end balance $ 100,162 $ 34,035 The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2020 through December 31, 2023 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12 – Commitments and Contingencies Lease Obligations The Company leases administrative, R&D, sales and marketing and manufacturing facilities under non-cancellable operating leases and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. During the year December 31, 2023, the Company amended two operating leases to extend the lease term and entered into two new operating leases. As a result, the Company recognized additional operating lease liabilities and corresponding operating right-of-use assets of $ 3,203,146 For the year ended December 31, 2023, components of lease expense are summarized as follows: Schedule of Lease Expense Year Ended December 31, 2023 Operating lease costs $ 813,743 Short-term lease costs 198,261 Total lease costs $ 1,012,004 As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows: Schedule of Maturities on Company Lease Liabilities Year Ending December 31, 2024 $ 996,676 2025 1,018,383 2026 714,630 2027 300,591 Thereafter 308,462 Total lease payments 3,338,742 Less: imputed interest 348,175 Present value of operating lease liabilities 2,990,567 Less: current portion 838,387 Long-term portion $ 2,152,180 Other information related to operating leases was as follows: Schedule of Other Information Related to Operating Lease Year Ended December 31, 2023 Cash paid for operating leases included in operating cash flows $ 954,013 Remaining lease term of operating leases 3.7 Discount rate of operating leases 6.2 % Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two civil actions, one in the US and the other in the United Kingdom. Each of the civil actions is based on breach of contract claims against the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

Share Repurchase Program

Share Repurchase Program	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Share Repurchase Program	Note 13 – Share Repurchase Program In March 2022, the Company’s board of directors authorized a share repurchase program that would allow the Company to repurchase up to $ 30.0 For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented: Schedule of Treasury Stock Year Ended December 31, 2023 Balance, beginning of period 3,881,658 Repurchases of common stock 967,020 Balance, end of period 4,848,678

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 14 – Related Party Transactions The Company employs one person who is related to current or former executive officers. Seth Egan is the Company’s Director of Sales and Marketing, and is the son of Dwight Egan, the Company’s President and Chief Executive Officer and Chairman of the Board. During the year ended December 31, 2023, the total compensation paid to this person, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years 0.6 0.1 In August 2023, the Company entered into a services agreement with CoSara, the Company’s equity method investment, under which CoSara provides certain research and development consulting and support services. During the year ended December 31, 2023, the Company recognized $ 0.2

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events None.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.
Marketable Investment Securities	Marketable Investment Securities The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the consolidated statements of operations and comprehensive loss. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2023 total accounts receivable was $ 504,264 200,338 303,926 6,552,249 3,098,526 3,453,723
Equity-Method Investments	Equity-Method Investments Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.
Inventory	Inventory Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2023, the Company had $ 1,664,725 700,467 964,258 5,310,473 1,327,264 3,983,209 2,760,011 0
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets acquired in business combinations. Goodwill and indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives. During the years ended December 31, 2023 and 2022, the Company recognized impairment charges related to goodwill of $ 0 15,388,546
Long-lived Assets	Long-lived Assets Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. The Company reviews its long-lived assets, including property and equipment, indefinite-lived and finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.
Revenue Recognition	Revenue Recognition The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.
Grant Revenue	Grant Revenue The Company may submit applications to receive grant funding from governmental and non-governmental entities. The Company accounts for grants by analogizing to the contribution accounting model under ASC 958-605, Not-for-Profit Entities (“ASC 958”). Revenues from grants, contracts, and awards provided by governmental and non-governmental agencies are recorded based upon the terms of the specific agreements. The Company recognizes grant funding without conditions or continuing performance obligations as revenue in the consolidated statements of operations and comprehensive income (loss). The Company recognizes grant funding with conditions or continuing performance obligations as deferred revenue in the consolidated balance sheets if the conditions or performance obligations have not yet been met. The Company recognized grant funding revenue of $ 5.8 0.3
Deferred Revenue	Deferred Revenue Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.
Research and Development	Research and Development Research and development costs are expensed when incurred. The Company recorded $ 22,962,593 17,438,098
Stock-based Compensation	Stock-based Compensation The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority. Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies. Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period. Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive loss is comprised of net loss and unrealized gains and losses on marketable securities, net of income taxes.
Concentrations Risk and Significant Customers	Concentrations Risk and Significant Customers The Company had certain customers which were each responsible for generating 10 28 37 100 Three customers accounted for more than 10 97 61
Recently Issued Accounting Standards	Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to disclose annually additional information related to the company’s income tax rate reconciliation and income taxes paid during the period. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for the Company for full year 2025 reporting. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

Cash, Cash Equivalents, and F_2

Cash, Cash Equivalents, and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Schedule of Cash, Cash Equivalents and Marketable Investment Securities	The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category: Schedule of Cash, Cash Equivalents and Marketable Investment Securities December 31, 2023 Adjusted Cost Allowance for Credit Losses Total Unrealized Gains / (Losses) Fair Value Cash and Cash Equivalents Marketable Investment Securities Cash $ 4,317,449 $ - $ - $ 4,317,449 $ 4,317,449 $ - Level 1: Money market funds 10,599,429 - - 10,599,429 10,599,429 - Subtotal 10,599,429 - - 10,599,429 10,599,429 - Level 2: U.S. treasury securities 43,484,810 - 146,700 43,631,510 - 43,631,510 Subtotal 43,484,810 - 146,700 43,631,510 - 43,631,510 Total $ 58,401,688 $ - $ 146,700 $ 58,548,388 $ 14,916,878 $ 43,631,510 December 31, 2022 Adjusted Cost Allowance for Credit Losses Total Unrealized Gains / (Losses) Fair Value Cash and Cash Equivalents Marketable Securities Cash $ 12,834,444 $ - $ - $ 12,834,444 $ 12,834,444 $ - Level 1: Money market funds 146,359 - - 146,359 146,359 - Subtotal 146,359 - - 146,359 146,359 - Level 2: U.S. treasury securities 67,892,825 - 389,241 68,282,066 9,993,000 58,289,066 Subtotal 67,892,825 - 389,241 68,282,066 9,993,000 58,289,066 Total $ 80,873,628 $ - $ 389,241 $ 81,262,869 $ 22,973,803 $ 58,289,066

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets and Liabilities	The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022, by level within the fair value hierarchy: Schedule of Fair Value Assets and Liabilities (Level 1) (Level 2) (Level 3) Total December 31, 2023 (Level 1) (Level 2) (Level 3) Total Assets: Cash equivalents $ 13,806,864 $ - $ - $ 13,806,864 Marketable securities (U.S. treasury bills and notes) - 43,631,510 - 43,631,510 Total assets measured at fair value $ 13,806,864 $ 43,631,510 $ - $ 57,438,374 Liabilities: Contingent consideration - common stock $ - $ - $ 1,318,995 $ 1,318,995 Contingent consideration - warrants - - 320,780 320,780 Total liabilities measured at fair value $ - $ - $ 1,639,775 $ 1,639,775 (Level 1) (Level 2) (Level 3)  Total December 31, 2022 (Level 1) (Level 2) (Level 3) Total Assets: Cash equivalents $ 186,667 $ 9,993,000 $ - $ 10,179,667 Marketable securities (U.S. treasury bills and notes) - 58,289,066 - 58,289,066 Total assets measured at fair value $ 186,667 $ 68,282,066 $ - $ 68,468,733 Liabilities: Contingent consideration - common stock $ - $ - $ 2,499,147 $ 2,499,147 Contingent consideration - warrants - - 233,209 233,209 Total liabilities measured at fair value $ - $ - $ 2,732,356 $ 2,732,356
Schedule of Changes in the Fair Value Measurement	The changes for Level 3 items measured at fair value on a recurring basis are as follows: Schedule of Changes in the Fair Value Measurement Fair value as of December 31, 2022 $ 2,732,356 Change in fair value of contingent consideration issued for business acquisitions (1,092,581 ) Fair value as of December 31, 2023 $ 1,639,775
Schedule of Contingent Consideration Common Stock and Warrants	Schedule of Contingent Consideration Common Stock and Warrants December 31, 2023 December 31, 2022 Stock price $ 1.33 $ 2.52 Strike price $ 9.13 $ 9.13 Volatility 187.5 % 75.0 % Risk-free rate 4.0 % 4.1 % Expected term (years) 3.0 4.0

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following: Schedule of Property and Equipment Estimated December 31, Useful Lives in years 2023 2022 Lab equipment 3 5 $ 4,545,908 $ 3,574,730 Leasehold improvements 0 5 548,648 224,957 Office equipment, furniture and other 2 5 173,668 112,044 Less accumulated depreciation and amortization (2,232,495 ) (1,372,248 ) Fixed assets, net $ 3,035,729 $ 2,539,483

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Schedule of Goodwill Balance as of December 31, 2021 $ 14,706,818 Measurement period adjustments 681,728 Goodwill impairment charges (15,388,546 ) Balance as of December 31, 2022 $ -
Schedule of Intangible Assets, Net	Intangible assets, net consisted of the following: Schedule of Intangible Assets, Net December 31, 2023 Weighted-Average Gross Net Useful Life (1) Carrying Accumulated Carrying (in Years) Amount Amortization Amount In-process research and development Indefinite $  26,101,000 $ - $ 26,101,000 Non-competition agreements 2.7 1,094,000 (791,333 ) 302,667 Total intangible assets $ 27,195,000 $ (791,333 ) $ 26,403,667 December 31, 2022 Weighted-Average Gross Net Useful Life (1) Carrying Accumulated Carrying (in Years) Amount Amortization Amount In-process research and development Indefinite $ 26,101,000 $ - $ 26,101,000 Non-competition agreements 2.7 1,094,000 (426,667 ) 667,333 Total intangible assets $ 27,195,000 $ (426,667 ) $ 26,768,333 (1) Based on weighted-average useful life established as of the acquisition date.
Schedule of Future Amortization Expense	The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2023 is as follows: Schedule of Future Amortization Expense Year Ending December 31, Amortization Expense 2024 302,667 Total $ 302,667

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: Schedule of Accrued Expenses December 31, 2023 December 31, 2022 Payroll liabilities $ 1,643,186 $ 428,354 Distributor commissions 9,958 159,725 Other accrued liabilities 519,815 346,368 Total accrued expenses $ 2,172,959 $ 934,447

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Summary of Revenue by Geographic Area	The following table sets forth revenue by geographic area: Summary of Revenue by Geographic Area 2023 2022 Years Ended December 31, 2023 2022 United States Product revenue $ 659,618 $ 24,671,554 Grant revenue 5,820,565 - Total United States 6,480,183 24,671,554 Rest of World Product revenue 331,855 9,546,655 Grant revenue - - Total Rest of World 331,855 9,546,655 Total $ 6,812,038 $ 34,218,209 Revenue geographic area $ 6,812,038 $ 34,218,209 Percentage of revenue by area: United States 95 % 72 % Rest of World 5 % 28 %
Schedule of Deferred Revenue	Changes in the Company’s deferred revenue balance for the year ended December 31, 2023 were as follows: Schedule of Deferred Revenue Balance as of December 31, 2022 $ - Increase due to prepayments from customers 32,570 Increase due to grant funding awarded 329,879 Balance as of December, 2023 $ 362,449

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Basis and Diluted Earnings Per Share	The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2023 and 2022: Schedule of Basis and Diluted Earnings Per Share 2023 2022 Years Ended December 31, 2023 2022 Numerator Net loss, as reported $ (35,332,865 ) $ (14,238,249 ) Denominator Weighted average shares, basic 29,346,599 31,479,028 Dilutive effect of stock options, warrants and RSUs - - Shares used to compute diluted earnings per share 29,346,599 31,479,028 Basic earnings per share $ (1.20 ) $ (0.45 ) Diluted earnings per share $ (1.20 ) $ (0.45 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Option Activity	The following table summarizes option activity during the years ended December 31, 2023 and 2022: Schedule of Option Activity Number of Options Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2021 1,111,363 $ 2.12 $ 1.31 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised (70,791 ) 1.10 0.51 Outstanding at December 31, 2022 1,040,572 $ 2.19 $ 1.37 5.88 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised - - - Outstanding at December 31, 2023 1,040,572 $ 2.19 $ 1.37 4.89 Exercisable at December 31, 2023 1,040,572 $ 2.19 $ 1.37 4.89
Schedule of Outstanding Restricted Stock Units and Related Party	The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022: Schedule of Outstanding Restricted Stock Units and Related Party Number of RSUs Weighted Average Grant Date Fair Value Unvested at December 31, 2021 1,267,415 $ 9.94 Granted 1,925,476 5.66 Vested (725,166 ) 8.66 Forfeited/Cancelled (41,000 ) 8.31 Unvested at December 31, 2022 2,426,725 $ 6.95 Granted 1,948,750 1.92 Vested (1,354,081 ) 6.17 Forfeited/Cancelled (95,897 ) 6.16 Unvested at December 31, 2023 2,925,497 $ 3.99
Schedule of Warrant Activity	The following table summarizes warrant activity during the years ended December 31, 2023 and 2022: Schedule of Warrant Activity Number of Warrants Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2021 526,281 $ 8.15 $ 4.01 4.7 Issued for adjustments to contingent purchase consideration 8,719 9.13 1.88 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised (50,000 ) 2.00 1.22 Outstanding at December 31, 2022 485,000 $ 8.81 $ 2.43 4.0 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised - - - Outstanding at December 31, 2023 485,000 $ 8.81 $ 1.29 3.0
Schedule of Recognized Stock-based Compensation Expense	The Company recognized stock-based compensation expense as follows: Schedule of Recognized Stock-based Compensation Expense 2023 2022 Years Ended December 31, 2023 2022 Cost of sales $ 46,586 $ 63,058 Sales and marketing 2,153,974 1,866,116 General and administrative 4,933,822 4,050,967 Research and development 1,202,473 1,563,082 Total stock-based compensation expense $ 8,336,855 $ 7,543,223

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Components Income Tax Provision	The components of the provision (benefit) for income taxes consists of the following for the years ended December 31, 2023 and 2022: Schedule of Components Income Tax Provision 2023  2022 Year Ended December 31, 2023 2022 Current: Federal $ 84,435 $ 563,821 State (540,240 ) (266,248 ) Total current $ (455,805 ) $ 297,573 Deferred: Federal (7,228,611 ) (3,945,090 ) State (2,068,509 ) (961,468 ) Change in valuation allowance 6,975,234 - Total deferred (2,321,886 ) (4,906,558 ) Total income tax benefit $ (2,777,691 ) $ (4,608,985 )
Schedule of Benefit from Income Taxes and Effective Tax Rates	A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows: Schedule of Benefit from Income Taxes and Effective Tax Rates 2023 2022 Year Ended December 31, 2023 2022 Federal income tax expense at statutory rate 21.0 % 21.0 % State income tax expense, net of federal tax benefit 1.6 % 4.8 % Permanent differences: - Foreign derived intangible income deduction 0.0 % 1.4 % - Stock based compensation -3.5 % -3.6 % - Contingent consideration remeasurement 0.6 % 8.8 % - Goodwill impairment 0.0 % -17.1 % - Other permanent differences -0.2 % -0.6 % Research and development credits 4.6 % 11.1 % Change in uncertain tax positions 1.2 % -2.1 % Change in valuation allowance -18.3 % 0.0 % Other 0.3 % 0.8 % Effective income tax rate 7.3 % 24.5 %
Schedule of Deferred Tax Assets and Liabilities	Net deferred tax liabilities consist of the following components as of December 31, 2023 and 2022: Schedule of Deferred Tax Assets and Liabilities 2023 2022 December 31, 2023 2022 Deferred tax assets: Accrued liabilities $ 58,158 $ 98,141 Reserves and allowances 734,631 765,004 Deferred compensation 620,551 566,076 Section 174 costs 7,337,629 3,460,159 Lease liability 742,131 85,899 UNICAP 43,943 168,936 Net operating loss carryforwards 4,040,601 - Research and development credits 1,688,255 - Total gross deferred tax assets 15,265,899 5,144,215 Less valuation allowance (6,938,829 ) - Total deferred tax assets 8,327,070 5,144,215 Deferred tax liabilities: Property and equipment, net (672,416 ) (609,261 ) Intangibles, net (6,552,255 ) (6,608,914 ) Prepaids (329,768 ) (156,053 ) Right of use asset (736,226 ) (91,873 ) Other comprehensive income (36,405 ) (96,101 ) Other - - Total deferred tax liabilities (8,327,070 ) (7,562,202 ) Net deferred tax liability $ - $ (2,417,987 )
Schedule of Unrecognized Tax Benefits	Schedule of Unrecognized Tax Benefits December 31, 2023 2022 Unrecognized tax benefits at the beginning of the year $ 1,469,577 $ 1,067,853 Gross increases - current year tax positions 273,569 1,045,590 Gross increases - prior year tax positions 66,127 34,035 Gross decreases - prior year tax positions (730,842 ) (677,901 ) Unrecognized tax benefits at end of year $ 1,078,431 $ 1,469,577 Interest and penalties in year-end balance $ 100,162 $ 34,035

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Expense	For the year ended December 31, 2023, components of lease expense are summarized as follows: Schedule of Lease Expense Year Ended December 31, 2023 Operating lease costs $ 813,743 Short-term lease costs 198,261 Total lease costs $ 1,012,004
Schedule of Maturities on Company Lease Liabilities	As of December 31, 2023, the maturities of the Company’s lease liabilities are as follows: Schedule of Maturities on Company Lease Liabilities Year Ending December 31, 2024 $ 996,676 2025 1,018,383 2026 714,630 2027 300,591 Thereafter 308,462 Total lease payments 3,338,742 Less: imputed interest 348,175 Present value of operating lease liabilities 2,990,567 Less: current portion 838,387 Long-term portion $ 2,152,180
Schedule of Other Information Related to Operating Lease	Other information related to operating leases was as follows: Schedule of Other Information Related to Operating Lease Year Ended December 31, 2023 Cash paid for operating leases included in operating cash flows $ 954,013 Remaining lease term of operating leases 3.7 Discount rate of operating leases 6.2 %

Share Repurchase Program (Table

Share Repurchase Program (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Treasury Stock	Schedule of Treasury Stock Year Ended December 31, 2023 Balance, beginning of period 3,881,658 Repurchases of common stock 967,020 Balance, end of period 4,848,678

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Accounts receivable	$ 504,264	$ 6,552,249
Doubtful accounts	200,338	3,098,526
Accounts receivable, net	303,926	3,453,723
Inventory	1,664,725	5,310,473
Inventory, finished goods, gross	700,467	1,327,264
Inventory, raw materials, gross	964,258	3,983,209
Inventory reserves	2,760,011	0
Impairment charges	0	15,388,546
Grant funding revenue	5,800,000
Deferred revenue	300,000
Research and development	$ 22,962,593	$ 17,438,098
Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage	10%	10%
Two Customers [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage	10%	10%
Two Customers [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration risk percentage	28%
One Customer [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration risk percentage		37%
One Granting Agency [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration risk percentage	100%
Customers Together [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage	97%	61%

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Marketable Investment Securities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 58,401,688	$ 80,873,628
Allowance for Credit Losses
Total Unrealized Gains / (Losses)	146,700	389,241
Fair Value	58,548,388	81,262,869
Cash and Cash Equivalents	14,916,878	22,973,803
Marketable Securities	43,631,510	58,289,066
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	10,599,429	146,359
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value	10,599,429	146,359
Cash and Cash Equivalents	10,599,429	146,359
Marketable Securities
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	43,484,810	67,892,825
Allowance for Credit Losses
Total Unrealized Gains / (Losses)	146,700	389,241
Fair Value	43,631,510	68,282,066
Cash and Cash Equivalents		9,993,000
Marketable Securities	43,631,510	58,289,066
Cash [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	4,317,449	12,834,444
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value	4,317,449	12,834,444
Cash and Cash Equivalents	4,317,449	12,834,444
Marketable Securities
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	10,599,429	146,359
Allowance for Credit Losses
Total Unrealized Gains / (Losses)
Fair Value	10,599,429	146,359
Cash and Cash Equivalents	10,599,429	146,359
Marketable Securities
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	43,484,810	67,892,825
Allowance for Credit Losses
Total Unrealized Gains / (Losses)	146,700	389,241
Fair Value	43,631,510	68,282,066
Cash and Cash Equivalents		9,993,000
Marketable Securities	$ 43,631,510	$ 58,289,066

Schedule of Fair Value Assets a

Schedule of Fair Value Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (U.S. treasury bills and notes)	$ 43,631,510	$ 58,289,066
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (U.S. treasury bills and notes)
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (U.S. treasury bills and notes)	43,631,510	58,289,066
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	13,806,864	10,179,667
Marketable securities (U.S. treasury bills and notes)	43,631,510	58,289,066
Total assets measured at fair value	57,438,374	68,468,733
Contingent consideration - common stock	1,318,995	2,499,147
Contingent consideration - warrants	320,780	233,209
Total liabilities measured at fair value	1,639,775	2,732,356
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	13,806,864	186,667
Marketable securities (U.S. treasury bills and notes)
Total assets measured at fair value	13,806,864	186,667
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		9,993,000
Marketable securities (U.S. treasury bills and notes)	43,631,510	58,289,066
Total assets measured at fair value	43,631,510	68,282,066
Contingent consideration - common stock
Contingent consideration - warrants
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Marketable securities (U.S. treasury bills and notes)
Total assets measured at fair value
Contingent consideration - common stock	1,318,995	2,499,147
Contingent consideration - warrants	320,780	233,209
Total liabilities measured at fair value	$ 1,639,775	$ 2,732,356

Schedule of Changes in the Fair

Schedule of Changes in the Fair Value Measurement (Details) - Fair Value, Recurring [Member]	12 Months Ended
	Dec. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value as of December 31, 2022	$ 2,732,356
Change in fair value of contingent consideration issued for business acquisitions	(1,092,581)
Fair value as of December 31, 2023	$ 1,639,775

Schedule of Contingent Consider

Schedule of Contingent Consideration Common Stock and Warrants (Details)	Dec. 31, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term		4 years
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	1.33	2.52
Measurement Input Strike Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	9.13	9.13
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	1.875	0.750
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0.040	0.041
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term	3 years

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (2,232,495)	$ (1,372,248)
Property and equipment, net	3,035,729	2,539,483
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,545,908	3,574,730
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years
Leaseholds and Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	0 years
Leaseholds and Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 548,648	224,957
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 173,668	$ 112,044
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	2 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years

Schedule of Goodwill (Details)

Schedule of Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwil - beginning		$ 14,706,818
Measurement period adjustments		681,728
Goodwill impairment charges		(15,388,546)
Goodwill - ending

Schedule of Intangible Assets,

Schedule of Intangible Assets, Net (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		$ 27,195,000	$ 27,195,000
Less accumulated amortization		(791,333)	(426,667)
Intangible assets, net		$ 26,403,667	$ 26,768,333
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives in years, term	[1]	Indefinite	Indefinite
Intangible assets, gross		$ 26,101,000	$ 26,101,000
Less accumulated amortization
Intangible assets, net		26,101,000	26,101,000
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		1,094,000	1,094,000
Less accumulated amortization		(791,333)	(426,667)
Intangible assets, net		$ 302,667	$ 667,333
Estimated useful lives in years	[1]	2 years 8 months 12 days	2 years 8 months 12 days
[1]Based on weighted-average useful life established as of the acquisition date.

Schedule of Future Amortization

Schedule of Future Amortization Expense (Details)	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 302,667
Total	$ 302,667

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill			$ 14,706,818

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Payroll liabilities	$ 1,643,186	$ 428,354
Distributor commissions	9,958	159,725
Other accrued liabilities	519,815	346,368
Total accrued expenses	$ 2,172,959	$ 934,447

Summary of Revenue by Geographi

Summary of Revenue by Geographic Area (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue geographic area	$ 6,812,038	$ 34,218,209
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenue geographic area	$ 6,480,183	$ 24,671,554
UNITED STATES | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of revenue	95%	72%
UNITED STATES | Product [Member]
Disaggregation of Revenue [Line Items]
Revenue geographic area	$ 659,618	$ 24,671,554
UNITED STATES | Grant [Member]
Disaggregation of Revenue [Line Items]
Revenue geographic area	5,820,565
Rest of World [Member]
Disaggregation of Revenue [Line Items]
Revenue geographic area	$ 331,855	$ 9,546,655
Rest of World [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of revenue	5%	28%
Rest of World [Member] | Product [Member]
Disaggregation of Revenue [Line Items]
Revenue geographic area	$ 331,855	$ 9,546,655
Rest of World [Member] | Grant [Member]
Disaggregation of Revenue [Line Items]
Revenue geographic area

Schedule of Deferred Revenue (D

Schedule of Deferred Revenue (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Revenue from Contract with Customer [Abstract]
Deferred revenue, beginning balance
Increase due to prepayments from customers	32,570
Increase due to prepayments from grants received	329,879
Deferred revenue, ending balance	$ 362,449

Schedule of Basis and Diluted E

Schedule of Basis and Diluted Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net loss, as reported	$ (35,332,865)	$ (14,238,249)
Weighted average shares, basic	29,346,599	31,479,028
Dilutive effect of stock options, warrants and RSUs
Shares used to compute diluted earnings per share	29,346,599	31,479,028
Basic earnings per share	$ (1.20)	$ (0.45)
Diluted earnings per share	$ (1.20)	$ (0.45)

Earnings per Share (Details Nar

Earnings per Share (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted earnings per share	0	0
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted earnings per share	2,618,362	1,443,238
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted earnings per share	512,112	50,000
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted earnings per share	1,400,000	1,400,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted earnings per share	465,000	465,000

Schedule of Option Activity (De

Schedule of Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning	1,040,572	1,111,363
Weighted Average Exercise Price Outstanding, Beginning	$ 2.19	$ 2.12
Weighted Average Fair Value Outstanding, Ending	$ 1.37	$ 1.31
Number of Options Outstanding, Granted
Weighted Average Exercise Price Granted
Weighted Average Fair Value Granted
Number of Options Outstanding, Expired
Weighted Average Exercise Price Expired
Weighted Average Fair Value Expired
Number of Options Outstanding, Forfeited/Cancelled
Weighted Average Exercise Price Forfeited/Cancelled
Weighted Average Fair Value Forfeited/Cancelled
Number of Options Outstanding, Exercised		(70,791)
Weighted Average Exercise Price Exercised		$ 1.10
Weighted Average Fair Value Exercised		$ 0.51
Weighted-average Remaining Contractual Life (years) Outstanding, Beginning	5 years 10 months 17 days
Number of Options Outstanding, Ending	1,040,572	1,040,572
Weighted Average Exercise Price Outstanding, Ending	$ 2.19	$ 2.19
Weighted-average Remaining Contractual Life (years) Outstanding, Ending	4 years 10 months 20 days
Number of Options Exercisable Ending	1,040,572
Weighted Average Exercise Price, Exercisable Ending	$ 2.19
Weighted Average Fair Value, Exercisable Ending	$ 1.37
Weighted-average Remaining Contractual Life (years), Exercisable Ending	4 years 10 months 20 days

Schedule of Outstanding Restric

Schedule of Outstanding Restricted Stock Units and Related Party (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding Beginning	2,426,725	1,267,415
Weighted Average Grant Date Fair Value, Outstanding Beginning	$ 6.95	$ 9.94
Number of Restricted Stock Units, Granted	1,948,750	1,925,476
Weighted Average Grant Date Fair Value, Granted	$ 1.92	$ 5.66
Number of Restricted Stock Units, Vested	(1,354,081)	(725,166)
Weighted Average Grant Date Fair Value, Vested	$ 6.17	$ 8.66
Number of Restricted Stock Units, Forfeited/Cancelled	(95,897)	(41,000)
Weighted Average Grant Date Fair Value, Forfeited/Cancelled	$ 6.16	$ 8.31
Number of Restricted Stock Units, Outstanding Ending	2,925,497	2,426,725
Weighted Average Grant Date Fair Value, Outstanding Ending	$ 3.99	$ 6.95

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number of Warrants Outstanding, Beginning	485,000	526,281
Weighted Average Exercise Price, Beginning	$ 8.81	$ 8.15
Weighted Average fair value, Beginning	$ 2.43	$ 4.01
Weighted-average Remaining Contractual Life (Years) Outstanding		4 years 8 months 12 days
Number of Warrants Outstanding, Issued		8,719
Weighted Average Exercise Price, Issued		$ 9.13
Weighted Average Fair Value, Issued		$ 1.88
Number of Warrants Outstanding, Granted
Weighted Average Exercise Price, Granted
Weighted Average Fair Value, Granted
Number of Warrants Outstanding, Expired
Weighted Average Exercise Price, Expired
Weighted Average Fair Value, Expired
Number of Warrants Outstanding, Forfeited/Cancelled
Weighted Average Exercise Price, Forfeited/Cancelled
Weighted Average Fair Value, Forfeited/Cancelled
Number of Warrants Outstanding, Exercised		(50,000)
Weighted Average Exercise Price, Exercised		$ 2
Weighted Average Fair Value, Exercised		$ 1.22
Weighted-average Remaining Contractual Life (Years) Outstanding	3 years	4 years
Number of Warrants Outstanding, Ending	485,000	485,000
Weighted Average Exercise Price, Ending	$ 8.81
Weighted Average Fair Value, Ending	$ 1.29

Schedule of Recognized Stock-ba

Schedule of Recognized Stock-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 8,336,855	$ 7,543,223
Cost of Sales [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	46,586	63,058
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,153,974	1,866,116
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	4,933,822	4,050,967
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,202,473	$ 1,563,082

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average period	4 years 10 months 20 days
Warrants purchase	465,000
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Aggregate intrinsic value of options outstanding	$ 0
Intrinsic value of warrants exercised	$ 0	$ 300,000
Warrants exercisable	20,000
Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Intrinsic value of options value exercised	$ 0	400,000
Aggregate intrinsic value of options outstanding	200,000	$ 800,000
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation	$ 9,500,000
Weighted average period	1 year 8 months 12 days
2015 Long Term Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common shares availalble for issuance	4,357,937		12,000,000

Schedule of Components Income T

Schedule of Components Income Tax Provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 84,435	$ 563,821
State	(540,240)	(266,248)
Total current	(455,805)	297,573
Deferred:
Federal	(7,228,611)	(3,945,090)
State	(2,068,509)	(961,468)
Change in valuation allowance	6,975,234
Total deferred	(2,321,886)	(4,906,558)
Total income tax benefit	$ (2,777,691)	$ (4,608,985)

Schedule of Benefit from Income

Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal income tax expense at statutory rate	21%	21%
State income tax expense, net of federal tax benefit	1.60%	4.80%
Permanent differences:
- Foreign derived intangible income deduction	0%	1.40%
- Stock based compensation	(3.50%)	(3.60%)
- Contingent consideration remeasurement	0.60%	8.80%
- Goodwill impairment	0%	(17.10%)
- Other permanent differences	(0.20%)	(0.60%)
Research and development credits	4.60%	11.10%
Change in uncertain tax positions	1.20%	(2.10%)
Change in valuation allowance	(18.30%)	0%
Other	0.30%	0.80%
Effective income tax rate	7.30%	24.50%

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Accrued liabilities	$ 58,158	$ 98,141
Reserves and allowances	734,631	765,004
Deferred compensation	620,551	566,076
Section 174 costs	7,337,629	3,460,159
Lease liability	742,131	85,899
UNICAP	43,943	168,936
Net operating loss carryforwards	4,040,601
Research and development credits	1,688,255
Total gross deferred tax assets	15,265,899	5,144,215
Less valuation allowance	(6,938,829)
Total deferred tax assets	8,327,070	5,144,215
Deferred tax liabilities:
Property and equipment, net	(672,416)	(609,261)
Intangibles, net	(6,552,255)	(6,608,914)
Prepaids	(329,768)	(156,053)
Right of use asset	(736,226)	(91,873)
Other comprehensive income	(36,405)	(96,101)
Other
Total deferred tax liabilities	(8,327,070)	(7,562,202)
Net deferred tax liability		$ (2,417,987)

Schedule of Unrecognized Tax Be

Schedule of Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Unrecognized tax benefits at the beginning of the year	$ 1,469,577	$ 1,067,853
Gross increases- current year tax positions	273,569	1,045,590
Gross increases- prior year tax positions	66,127	34,035
Gross decreases - prior year tax positions	(730,842)	(677,901)
Unrecognized tax benefits at end of year	1,078,431	1,469,577
Interest and penalties in year-end balance	$ 100,162	$ 34,035

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carry-forwards	$ 16,300,000
Research and development credit carry forwards	1,400,000
State net operating loss carryforwards	16,900,000
State research and development credit carryforwards	800,000
Unrecognized tax benefits that would impact effective tax rate	$ 1,078,431	$ 1,469,577

Schedule of Lease Expense (Deta

Schedule of Lease Expense (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating lease costs	$ 813,743
Short-term lease costs	198,261
Total lease costs	$ 1,012,004

Schedule of Maturities on Compa

Schedule of Maturities on Company Lease Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2024	$ 996,676
2025	1,018,383
2026	714,630
2027	300,591
Thereafter	308,462
Total lease payments	3,338,742
Less: imputed interest	348,175
Present value of operating lease liabilities	2,990,567
Less: current portion	838,387	$ 297,209
Long-term portion	$ 2,152,180	$ 50,708

Schedule of Other Information R

Schedule of Other Information Related to Operating Lease (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Cash paid for operating leases included in operating cash flows	$ 954,013
Remaining lease term of operating leases	3 years 8 months 12 days
Discount rate of operating leases	6.20%

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease liabilities	$ 2,990,567
Lease Amendment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease liabilities	$ 3,203,146

Schedule of Treasury Stock (Det

Schedule of Treasury Stock (Details)	12 Months Ended
	Dec. 31, 2023 shares
Equity [Abstract]
Treasury stock, Beginning Balance	3,881,658
Repurchases of common stock	967,020
Treasury stock, Ending Balance	4,848,678

Share Repurchase Program (Detai

Share Repurchase Program (Details Narrative) $ in Millions	Mar. 31, 2022 USD ($)
Equity [Abstract]
Stock repurchase program authorized amount	$ 30

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Research and development expenses	$ 22,962,593	$ 17,438,098
Seth Egan [Member]
Related Party Transaction [Line Items]
Share based payment, vesting period	3 years
Fair value of equity awards	$ 600,000
Winston Egan [Member]
Related Party Transaction [Line Items]
Fair value of equity awards	100,000
CoSara Diagnostics Pvt Ltd [Member]
Related Party Transaction [Line Items]
Research and development expenses	$ 200,000